News

Search:

FDA Backs HIV Prevention Drug In Letter Denying Citizen Petition

0 Likes

The US Food and Drug Administration (FDA) this week published a citizen petition denial to a group seeking to pre-emptively block the approval of a supplemental New Drug Application (sNDA) for Gilead Read More...

Tags:

AIDS

AIDS Healthcare Foundation

Citizen Petition

FDA

Gilead

HIV

PrEP

sNDA

Truvada

FDA Approves Landmark HIV Prevention Pill

0 Likes

The US Food and Drug Administration's (FDA) drug regulatory division announced the approval of a new indication for Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), making it the first Read More...

Tags:

AIDS

FDA

Gilead

Hamburg

HIV

Truvada

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Most Viewed
Most Popular

Most Viewed

China's SFDA Becomes CFDA amidst Consolidation of Power and New Leadership 25 March 2013
FDA Plans Huge Cardiovascular Registry With Focus on Medical Devices 2 April 2013
In Unprecedented Shift, EU Parliament Proposes Premarket Authorization for Medical Devices 15 April 2013
Goodbye, KFDA: Korean Regulator Gets New Name, Decentralized Authority After Reorganization 28 March 2013
FDA Gets Go-Ahead for Study of DTC Advertising and Social Media 18 April 2013
UPDATED: President's Budget Proposal Calls for Small Increases at FDA, but Big Changes for Industry 11 April 2013
IBM Awarded Huge Contract to Modernize Regulatory Review Processes at FDA 29 April 2013
New FDA Document Clarifies IND Process for Drugs, Biologics and Biosimilars 30 April 2013

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

FDA Backs HIV Prevention Drug In Letter Denying Citizen Petition

FDA Approves Landmark HIV Prevention Pill

Get RF Today